Psychedelics Encyclopedia

Product Information

Thompson, M.A.; Moon, E.; Kim, U.J.; Xu, J.; Siciliano, M.J.; Weinshilboum, R.M. Human indolethylamine N-methyltransferase: cDNA cloning and expression, gene cloning, and chromosomal localization. Genomics 1999, 61, 285–297. Howes, O.H.; Kaar, S.J. Antipsychotic drugs: Challenges and future directions. World Psychiatry 2018, 17, 170–171.

Lally, J.; Ajnakina, O.; Di Forti, M.; Trotta, A.; Demjaha, A.; Kolliakou, A.; Mondelli, V.; Reis Marques, T.; Pariante, C.; Dazzan, P.; et al. Two distinct patterns of treatment resistance: Clinical predictors of treatment resistance in first-episode schizophrenia spectrum psychoses. Psychol. Med. 2016, 46, 3231–3240. Kane, J.; Honigfeld, G.; Singer, J.; Meltzer, H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry 1988, 45, 789–796. Archaeological evidence suggests psychoactive plants have been ingested the world over for millennia, 2 and there are many examples in the literature of anthropology and ethnobotany of this leading to the appearance of ostensible psi phenomena 3– despite reservations on the part of anthropologists against reporting them. 4 Reports of paranormal experiences in this context became more frequent following the discovery of psychedelic compounds by the academic community, and their popularization by the novelist Aldous Huxley 5 and others. This attracted the attention of parapsychologists, who embarked on research of psi in relation to psychedelics, primarily from the 1950s and 1960s 6. JB Rhine, the founder of parapsychology as an experimental science, ran informal psychedelic sessions in 1961 in collaboration with the then Harvard psychologists Timothy Leary and Richard Alpert, 7 although the sessions apparently generated too much spontaneous laughter for anyone to credibly test for anything. 8Richards, W.A.; Rhead, J.C.; Dileo, F.B.; Yensen, R.; Kurland, A.A. The Peak Experience Variable in DPT-Assisted Psychotherapy with Cancer Patients. J. Psychedelic Drugs 1977, 9, 1–10. Richards, W.A.; Rhead, J.C.; Grof, S.; Goodman, L.E.; Di Leo, F.; Rush, L. DPT as an Adjunct in Brief Psychotherapy with Cancer Patients. OMEGA—J. Death Dying 1980, 10, 9–26.

Giesler, P. (1984). Parapsychological anthropology: I. Multi-method approaches to the study of psi in the field setting. Journal of the American Society for Psychical Research 78, 287-328. Palmer, J. (1978). Extrasensory perception: Research findings. In Advances in Parapsychological Research: 2 Extrasensory Perception ed. by S. Krippner, 59-243). New York: Plenum Press. Frantzi, M.; Bhat, A.; Latosinska, A. Clinical proteomic biomarkers: Relevant issues on study design & technical considerations in biomarker development. Clin. Transl. Med. 2014, 3, 7. Dos Santos, R.G.; Bouso, J.C.; Rocha, J.M.; Rossi, G.N.; Hallak, J.E. The use of classic hallucinogens/psychedelics in a therapeutic context: Healthcare policy opportunities and challenges. Risk Manag. Healthc. Policy 2021, 14, 901. Hollister, L.E.; Hartman, A.M. Mescaline, lysergic acid diethylamide and psilocybin comparison of clinical syndromes, effects on color perception and biochemical measures. Compr. Psychiatry 1962, 3, 235–242.

Conclusion

British Association for Psychopharmacology of Schizophrenia. Evidence-Based Guidelines for the Pharmacological Treatment of Schizophrenia: Recommendations from the British Association for Psychopharmacology. Available online: https://www.bap.org.uk (accessed on 7 November 2021).